Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954486172> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2954486172 endingPage "iv66" @default.
- W2954486172 startingPage "iv65" @default.
- W2954486172 abstract "Introduction: Cabozantinib inhibits tyrosine kinases involved in tumor growth, angiogenesis, and immune regulation, including MET, VEGFR, and TAM kinases (Tyro3, AXL, MER). Cabozantinib is approved for the treatment of aHCC after prior sorafenib based on improved overall survival (OS) vs placebo in the phase 3 CELESTIAL trial (Abou-Alfa NEJM 2018). Standard of care for first-line treatment of aHCC is tyrosine kinase inhibition with sorafenib or lenvatinib, and phase 3 trials of immune checkpoint inhibitors (ICIs) in first- and second- line aHCC are ongoing. Cabozantinib may promote an immune-permissive tumor environment, which could enhance response to ICIs. Cabozantinib is being evaluated in combination with the anti-PD-L1 antibody atezolizumab in multiple tumor types including HCC in a phase 1 study; and dose, preliminary clinical activity, and safety have been established in aRCC (Agarwal Ann Oncol 2018). Atezolizumab in combination with bevacizumab, an anti-VEGF antibody, has shown preliminary clinical activity in first-line aHCC (Pishvaian Ann Oncol 2018). Here, we present the study design of a phase 3 trial of cabozantinib + atezolizumab vs sorafenib in patients with aHCC who have not received prior systemic therapy. Methods: This international, randomized, open-label phase 3 trial (NCT03755791) is evaluating the efficacy and safety of cabozantinib + atezolizumab vs sorafenib as first-line treatment for aHCC. Eligibility criteria include age ≥18 years, BCLC stage B or C, Child-Pugh A, ECOG PS 0 or 1, and measurable disease per RECIST 1.1. Patients are randomized 6:3:1 to an experimental arm of cabozantinib (40 mg qd) + atezolizumab (1200 mg infusion q3w), a control arm of sorafenib (400 mg bid), and an exploratory arm of cabozantinib monotherapy (60 mg qd). 640 patients are planned at ∼200 sites globally. Randomization is stratified by disease etiology (HBV [with or without HCV], HCV [without HBV], or other), region (Asia, other), and the presence of extrahepatic disease and/or macrovascular invasion (yes, no). OS and progression-free survival are co-primary endpoints and objective response rate is a secondary endpoint. Additional endpoints include safety, pharmacokinetics, and correlation of biomarker analyses with clinical outcomes. Enrollment in COSMIC-312 is ongoing." @default.
- W2954486172 created "2019-07-12" @default.
- W2954486172 creator A5003957234 @default.
- W2954486172 creator A5009078484 @default.
- W2954486172 creator A5019481117 @default.
- W2954486172 creator A5029171331 @default.
- W2954486172 creator A5060354852 @default.
- W2954486172 creator A5061825110 @default.
- W2954486172 creator A5065803904 @default.
- W2954486172 creator A5067784766 @default.
- W2954486172 creator A5073279579 @default.
- W2954486172 creator A5088566246 @default.
- W2954486172 date "2019-07-01" @default.
- W2954486172 modified "2023-10-13" @default.
- W2954486172 title "Phase 3 (COSMIC-312) study of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy" @default.
- W2954486172 doi "https://doi.org/10.1093/annonc/mdz155.237" @default.
- W2954486172 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32085245" @default.
- W2954486172 hasPublicationYear "2019" @default.
- W2954486172 type Work @default.
- W2954486172 sameAs 2954486172 @default.
- W2954486172 citedByCount "7" @default.
- W2954486172 countsByYear W29544861722020 @default.
- W2954486172 countsByYear W29544861722021 @default.
- W2954486172 countsByYear W29544861722022 @default.
- W2954486172 crossrefType "journal-article" @default.
- W2954486172 hasAuthorship W2954486172A5003957234 @default.
- W2954486172 hasAuthorship W2954486172A5009078484 @default.
- W2954486172 hasAuthorship W2954486172A5019481117 @default.
- W2954486172 hasAuthorship W2954486172A5029171331 @default.
- W2954486172 hasAuthorship W2954486172A5060354852 @default.
- W2954486172 hasAuthorship W2954486172A5061825110 @default.
- W2954486172 hasAuthorship W2954486172A5065803904 @default.
- W2954486172 hasAuthorship W2954486172A5067784766 @default.
- W2954486172 hasAuthorship W2954486172A5073279579 @default.
- W2954486172 hasAuthorship W2954486172A5088566246 @default.
- W2954486172 hasBestOaLocation W29544861721 @default.
- W2954486172 hasConcept C121608353 @default.
- W2954486172 hasConcept C126322002 @default.
- W2954486172 hasConcept C143998085 @default.
- W2954486172 hasConcept C2775949291 @default.
- W2954486172 hasConcept C2776264508 @default.
- W2954486172 hasConcept C2777701055 @default.
- W2954486172 hasConcept C2778019345 @default.
- W2954486172 hasConcept C2778695046 @default.
- W2954486172 hasConcept C2779551604 @default.
- W2954486172 hasConcept C2780057760 @default.
- W2954486172 hasConcept C2781064419 @default.
- W2954486172 hasConcept C535046627 @default.
- W2954486172 hasConcept C71924100 @default.
- W2954486172 hasConceptScore W2954486172C121608353 @default.
- W2954486172 hasConceptScore W2954486172C126322002 @default.
- W2954486172 hasConceptScore W2954486172C143998085 @default.
- W2954486172 hasConceptScore W2954486172C2775949291 @default.
- W2954486172 hasConceptScore W2954486172C2776264508 @default.
- W2954486172 hasConceptScore W2954486172C2777701055 @default.
- W2954486172 hasConceptScore W2954486172C2778019345 @default.
- W2954486172 hasConceptScore W2954486172C2778695046 @default.
- W2954486172 hasConceptScore W2954486172C2779551604 @default.
- W2954486172 hasConceptScore W2954486172C2780057760 @default.
- W2954486172 hasConceptScore W2954486172C2781064419 @default.
- W2954486172 hasConceptScore W2954486172C535046627 @default.
- W2954486172 hasConceptScore W2954486172C71924100 @default.
- W2954486172 hasLocation W29544861721 @default.
- W2954486172 hasOpenAccess W2954486172 @default.
- W2954486172 hasPrimaryLocation W29544861721 @default.
- W2954486172 hasRelatedWork W3084251940 @default.
- W2954486172 hasRelatedWork W3113175873 @default.
- W2954486172 hasRelatedWork W3133447762 @default.
- W2954486172 hasRelatedWork W3161522570 @default.
- W2954486172 hasRelatedWork W3199454979 @default.
- W2954486172 hasRelatedWork W4200114421 @default.
- W2954486172 hasRelatedWork W4281682363 @default.
- W2954486172 hasRelatedWork W4286512390 @default.
- W2954486172 hasRelatedWork W4292546856 @default.
- W2954486172 hasRelatedWork W4310189289 @default.
- W2954486172 hasVolume "30" @default.
- W2954486172 isParatext "false" @default.
- W2954486172 isRetracted "false" @default.
- W2954486172 magId "2954486172" @default.
- W2954486172 workType "article" @default.